Cambridgeshire and Peterborough
Formulary Chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders -
Parenteral progestogen-only contraceptives
Etonogestrel 68 mg implant
(Contraception - Implant)
Letters sent to healthcare professionals February 2020: Nexplanon (etonogestrel 68 mg, implant for subdermal use) - update to the insertion and removal instructions to minimise the risks of neurovascular injury and implant migration
MHRA Drug Safety Update February 2020: Nexplanon (etonogestrel) contraceptive implants - new insertion site to reduce rare risk of neurovascular injury and implant migration
NWAFT and Primary Care:
Restricted to women who find Depo-Provera unacceptable or where contra-indicated due to increased risk of bleeding and hematoma, i.e. bleeding disorders, anticoagulation.
at all other Trusts.
Drug Safety Update: Nexplanon (etonogestrel) contraceptive implants - reports of device in vasculature and lung
NICE CKS: Contraception - Progestogen-only methods
Non Formulary Items
Licensed only for short term use
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Available Over the Counter. Consider Self Care
Formulary - Can be prescribed in both secondary and primary care.
Formulary - Specialist Advice, secondary care advice provided for primary care initiation.
Formulary - Specialist initiation without shared care guidance.
Formulary - Specialist initiation with shared care guidance.
Restricted - Hospital only, not to be prescribed in primary care.
Not recommended for prescribing. Switch to alternative cost-effective option.
Not recommended for prescribing in primary or secondary care.
Not recommended as no formal application made for addition to the formulary. Contact relevant pharmacy team for further information.
Non-Formulary (category under review).